Erythropoietin levels in cardiac resynchronization therapy responders.
Cardiac resynchronization therapy (CRT) is an effective treatment strategy in patients with severe left ventricular dysfunction and those with evidence of electro-mechanical dyssynchrony. A prospective observational study was conducted in patients with severe symptomatic heart failure undergoing CRT implantation. Thirty patients were classified as either responders (9 patients), or non-responders (21 patients). The association between functional status, quality of life scores and CRT responder status with erythropoietin (EPO) levels was determined. The mean EPO levels among responders were 28.8±3.6 and 11.4±1.7 mIU/ml among non-responders. Elevated EPO levels in the absence of anemia and renal insufficiency effectively correlate with functional impairment and severe symptoms, which impair quality of life in patients undergoing CRT.
Jazrawi
Ayad
A
Clifford
Sarah
S
Machado
Christian
C
Daccarett
Marcos
M
D000368:Aged; D015415:Biomarkers / Q000097:blood; D058406:Cardiac Resynchronization Therapy; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000097:blood* / Q000628:therapy*
D015415:Biomarkers; D004921:Erythropoietin